Empower Clinics Inc (CSE:CBDT) (OTCMKTS:EPWCF) revealed on Wednesday that its corporate clinics business continues to go from strength to strength.
The vertically integrated health and life sciences firm runs a network of physician-staffed wellness clinics and patient visits increased by 800% last month (February) versus the same month in 2019.
The total patient visits came in at 1,817 in February 2020 compared to 227 in February 2019, the Vancouver-headquartered company said.
READ: Empower Clinics to create psilocybin and psychedelics division leveraging corporate wellness and franchise clinic network
"Patient volumes have remained strong to start the year in all clinics, continuing on our push for a record first quarter," said Dustin Klein, senior vice-president of business development and a director at Empower.
"Operational excellence each day, combined with exemplary care for the patient, sets us apart in the markets we serve."
Empower also revealed it had received "numerous" inquiries with both positive and supportive sentiment, after it announced its plans to create a psilocybin and psychedelics division.
Last week, the firm said it intends to leverage its existing clinic network, the developing franchise brand, its 165,000 patients and product development capability, to create psilocybin and psychedelics subsidiaries.
It noted that studies were finding that psilocybin – the active agent in magic mushrooms could treat addiction, depression, anxiety and mental health conditions like post-traumatic stress disorder (PTSD), and end-of-life psychological distress.
Steven McAuley, the chairman and CEO of Empower, added: "Getting positive reinforcement from researchers, physicians, advocates and practitioners about our intention to enter this developing field of study, gives me confidence that we have made the correct decision to leverage our corporate assets for psilocybin and psychedelics research and development."
Shares in Toronto were unchanged at C$0.045. In New York, they added 12.4% to US$0.0326.
Contact the author at [email protected]